{"changes":[{"companyHref":"/c/ugen-com","date":"2026-09-25","documentUrl":null,"domain":"ugen.com","fact":"latest round","name":"Wugen, Inc.","new":{"amountUsd":163043971,"date":"2025-09-08","lead":null,"type":null},"old":{"amountUsd":163043971,"date":"2025-09-08","lead":null,"type":"seed"},"publisher":"sec-edgar","reason":null,"retrievedAt":"2026-06-02","slug":"ugen-com","status":"attributed","url":"https://whoraisedwhat.com/c/ugen-com"}],"country":"US","description":"Wugen is a clinical-stage biotech developing off-the-shelf allogeneic cell therapies for hard-to-treat blood and solid tumors. Its programs target patients with cancers such as relapsed or refractory acute myeloid leukemia and T-cell malignancies. The company's Moneta platform engineers cytokine-induced memory natural-killer cells designed to be more durable and potent than conventional NK therapies.","domain":"ugen.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"health care","investors":[],"lat":38.625406,"lng":-90.190009,"location":"St. Louis, Missouri","name":"Wugen, Inc.","rounds":[{"amountQuarantined":false,"amountUsd":163043971,"currency":"USD","date":"2025-09-08","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-06-02","status":"attributed","url":null},"status":"attributed","type":null,"url":null}],"slug":"ugen-com","sources":[{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-06-02","status":"attributed","url":null},{"fact":"existence","publisher":"ugen.com","retrievedAt":"2026-06-02","status":"self-reported","url":"https://ugen.com"},{"fact":"description","publisher":"ugen.com","retrievedAt":"2026-06-02","status":"self-reported","url":"https://ugen.com"}],"stage":null,"techStack":[],"totalRaisedUsd":163043971,"updatedAt":"2026-06-02"}